Form 4: BioXcel Therapeutics Director Converts Restricted Stock Units to Common Stock

BioXcel Therapeutics Director David J. Mack converted 1,693 Restricted Stock Units into common stock on July 31, 2025, increasing his direct holdings of the company's shares.

Summary

• David J. Mack, a Director of BioXcel Therapeutics, Inc. (BTAI), converted 1,693 Restricted Stock Units (RSUs) into common stock.
• The transaction occurred on July 31, 2025.
• Following this conversion, Mr. Mack directly holds 15,237 shares of BioXcel Therapeutics common stock.
• Mr. Mack also directly holds 5,080 Restricted Stock Units after the reported transaction.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• Mr. Mack was initially granted 20,317 RSUs on November 21, 2024, which are vesting in twelve equal monthly installments beginning November 30, 2024, contingent on his continued service as a Director.

Sentiment

Score: 7

Explanation: The filing indicates a routine conversion of Restricted Stock Units into common stock by a director, which is a positive sign of vested equity compensation and increased direct ownership, aligning interests with shareholders. It is not a new open market purchase, but rather the realization of previously granted compensation.

Positives

• Director David J. Mack increased his direct beneficial ownership of BioXcel Therapeutics common stock by 1,693 shares through the conversion of Restricted Stock Units.
• The conversion of RSUs into common stock signifies the vesting of equity compensation, which generally aligns the director's financial interests with those of common shareholders.

Negatives

• None identified in this routine insider transaction filing.

Risks

• No specific risks are detailed in this transaction report, as it primarily discloses a change in beneficial ownership due to equity compensation vesting.

Future Outlook

This filing is a disclosure of a past transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• No direct management comments or quotes are typically included in a Form 4 filing, which is a transactional disclosure.

Industry Context

This Form 4 filing details a routine equity compensation event for a director, which is a standard practice across industries to align management and board interests with shareholder value. It does not provide broader industry trend insights.

Comparison to Industry Standards

• The conversion of Restricted Stock Units (RSUs) into common stock is a standard form of equity compensation for directors and executives across publicly traded companies, aligning with common industry practices for incentivizing long-term commitment and performance. No specific comparable companies or projects are detailed as this is a routine transaction.

Related Party Transactions

• The conversion of Restricted Stock Units into common stock is a related party transaction as it involves equity compensation granted by the issuer to a director.

Stakeholder Impact

• Shareholders: Increased alignment of the director's financial interests with those of common shareholders due to increased direct stock ownership.
• Employees/Management: Reinforces the company's commitment to equity-based compensation for its leadership.

Next Steps

• Remaining Restricted Stock Units will continue to vest in equal monthly installments, subject to the director's continued service.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Director Stock Ownership, Equity Compensation